Insights8 min read
Eugia’s CCTV findings, in FDA’s own words
From Form 483 narratives to the CDER reading-room file and June 2026 OAI coverage: how investigators used the plant’s own cameras — and cited blind spots — at Sangareddy.
Our India 483 corpus already flagged Eugia Pharma’s Sangareddy sites for camera-review failures in 2024 and again in early 2026. Public filings and FDA’s own reading-room text now let anyone read the same story without opening a redacted PDF dump.
What the company told the market
Aurobindo Pharma’s February 6, 2026 exchange disclosure stated that FDA inspected Eugia Unit-III (Pashamylaram, Sangareddy) from January 27 to February 6, 2026 and closed with 11 observations — described as procedural, with a commitment to respond in time. That filing is the board-level timestamp: inspection end and disclosure the same day.
What FDA wrote about the cameras
In the publicly posted Form FDA 483 / reading-room materials for Eugia Pharma Specialities Limited (February 2026), investigators did not treat CCTV as optional wallpaper. They treated it as the quality system’s eyes:
- “Poor aseptic practices and inadequate glove monitoring was observed during review of CCTV recordings of sterile production.”
- Critical setup and corrective interventions “cannot be monitored through existing viewing windows or closed-circuit television (CCTV) camera systems.”
- “The CCTV system serves as the primary method for Quality Assurance personnel to review filling operations and identify potential breaches in aseptic practices.”
That last sentence is the product thesis in FDA’s voice: when windows are not enough, cameras are how QA is expected to see the fill. Blind spots are then a CGMP problem — not an IT nicety.
How this lines up with our 483 corpus
The February 2024 Eugia 483 in our extractable set already described operators who were supposed to watch CCTV continuously but left for weight checks or bathroom breaks, with per-batch CCTV review removed by change control. The February 2026 narrative escalates the same theme: investigators reviewing recordings, finding aseptic/glove issues, and calling out coverage gaps on the critical path.
Then the classification landed
On June 12–13, 2026, press coverage of Aurobindo’s filing reported FDA classifying Unit-III as Official Action Indicated (OAI). The Hindu noted it was the second Eugia formulation plant near Hyderabad to draw OAI in less than a month (Kolthur / Ranga Reddy had been tagged OAI in May). That is the escalation ladder in public: 483 → classification → market narrative — at facilities where camera coverage was already on the observation sheet.
If CCTV is “the primary method for QA to review filling,” then continuous watch, retention, and coverage of critical interventions are not extras. They are the control FDA already audits.
Sources (web + FDA)
- FDA CDER FOIA reading room — Eugia Pharma Specialities (Feb 2026)
- Aurobindo exchange filing — Eugia Unit-III inspection close (6 Feb 2026)
- The Hindu — Eugia Unit-III classified OAI (13 Jun 2026)
- GroundStatus — FDA already treats plant cameras as a quality system